Legal specialists warn that Illinois legislation creating a prescription drug affordability board could face constitutional challenges from pharmaceutical manufacturers, mirroring litigation already underway in other states.
House Bill 3496, advanced narrowly in the Illinois House, would establish an independent board empowered to set upper payment limits on certain high-cost medicines sold in the state. Sponsors said the panel could adopt benchmarks tied to federally negotiated Medicare prices for some drugs.
Drug industry groups argue affordability boards do not address root causes of high prices and may conflict with federal patent and commerce laws. In Colorado, Amgen has sued over a board-imposed cap on the arthritis drug Enbrel, citing due process and preemption concerns.
Illinois lawmakers amended the proposal to limit reviews to two drugs per year outside automatic federal price adoptions and included a five-year sunset. Governor J.B. Pritzker has not said whether he would sign the measure, which still requires Senate approval. Constitutional lawyers said outcomes in Colorado could influence whether state price caps survive court scrutiny.
Representative Nabeela Syed, the bill’s House sponsor, said an independent board could work with multiple state agencies rather than sit inside one department. Pharmaceutical Research and Manufacturers of America argued that pharmacy benefit managers and health plans drive consumer costs more than manufacturer list prices. Appeals of board decisions would remain subject to judicial review under the amended proposal.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://dailycuratednews.substack.com/p/news-headlines-may-22-2026